UNIVERSITY OF UTAH

Clinical trials demonstrate that GLP-1 agonist drugs like semaglutide (Ozempic) can lead to a 13.9% loss of lean muscle mass, equivalent to approximately 20 years of age-related muscle decline.

Huntsman Cancer Institute at the University of Utah has achieved the first-ever allogeneic stem cell transplant using cells from a deceased donor, potentially revolutionizing treatment access for blood cancer patients.

Exposure to air pollution during pregnancy, particularly in the final month, increases newborn risk of requiring intensive care treatment by up to 35%, according to recent research published in Scientific Reports.

The RT CHARM phase III trial demonstrated that shortened radiation therapy (3 weeks) is noninferior to conventional 5-week treatment for breast cancer patients undergoing reconstruction after mastectomy.

Popular weight loss medications semaglutide (Wegovy) and tirzepatide (Zepbound) would need significant price reductions of 82% and 30% respectively to meet standard cost-effectiveness thresholds, according to new University of Chicago research.

A large NIH-funded clinical trial reveals that therapeutic hypothermia, previously successful in term infants, offers no protection against death or disability in preterm infants with hypoxic ischemic encephalopathy.

University of Utah researchers demonstrated safe and effective ultrasound-activated drug delivery to specific brain regions in non-human primates using multilayered nanoparticles.

A randomized clinical trial led by Huntsman Cancer Institute demonstrates that two sessions of high-dose vaginal brachytherapy are as effective as standard multiple low-dose treatments for endometrial cancer.